fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Abecma is the first CAR T approved for use in earlier lines of therapy for patients with relapsed or refractory multiple myeloma in Japan – BMS

Written by | 11 Dec 2023

Bristol-Myers Squibb K.K. announced that the company has received manufacturing and marketing approval of the supplemental New Drug Application for an additional indication for Abecma (idecabtagene vicleucel), a… read more.

Positive results from DREAMM-7 head-to-head phase III trial for Blenrep (belantamab mafodotin) in relapsed/refractory multiple myeloma – GSK

Written by | 3 Dec 2023

GSK plc announced positive headline results from a planned interim efficacy analysis of the DREAMM-7 head-to-head phase III trial evaluating belantamab mafodotin as a second-line treatment for relapsed… read more.

Elrexfio receives FDA accelerated approval for relapsed or refractory multiple myeloma – Pfizer

Written by | 19 Aug 2023

Pfizer Inc. announced the FDA has granted accelerated approval to Elrexfio (elranatamab-bcmm) for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received… read more.

FDA approves Talvey a first-in-class bispecific therapy for the treatment of patients with heavily pretreated multiple myeloma – Janssen Pharma

Written by | 15 Aug 2023

The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the FDA has granted accelerated approval of Talvey (talquetamab-tgvs), a first-in-class bispecific antibody for the treatment of adult… read more.

Presentation of longer-term data for Tecvayli showing a duration of response of 22 months in patients with r/r multiple myeloma – Janssen

Written by | 12 Jun 2023

The Janssen Pharmaceutical Companies of Johnson & Johnson announced long-term data from the pivotal Phase 1/II MajesTEC-1 study showing the sustained efficacy and safety of Tecvayli (teclistamab-cqyv) in… read more.

Investigative immunotherapy for multiple myeloma produces deep and durable response

Written by | 25 Aug 2021

One infusion of an investigative chimeric antigen receptor-T cell therapy (CAR-T cell therapy) for multiple myeloma has produced early and durable responses in heavily pretreated patients, researchers reported… read more.

EU approves Abecma for multiple myeloma – BMS

Written by | 23 Aug 2021

Bristol Myers Squibb announced that the European Commission has granted Conditional Marketing Authorization for Abecma (idecabtagene vicleucel; ide-cel), a first-in-class B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR)… read more.

Phase III MAIA study of Darzalex + Revlimid + dexamethasone shows survival benefits in multiple myeloma – Janssen Biotech

Written by | 20 Jun 2021

The Janssen Pharmaceutical Companies of Johnson & Johnson announced overall survival (OS) results from the Phase III MAIA (NCT02252172) study showing the addition of Darzalex (daratumumab) to lenalidomide… read more.

Health Canada approves Abecma for multiple myeloma – BMS

Written by | 2 Jun 2021

Bristol Myers Squibb Canada announced Health Canada has granted conditional approval (NOC/c) for Abecma (idecabtagene vicleucel; ide-cel) as the first and only B-cell maturation antigen (BCMA)-directed chimeric antigen… read more.

Melflufen filed with EMA for multiple myeloma – Oncopeptides AB

Written by | 20 Apr 2021

Oncopeptides AB announced that the Company has submitted an application to the European Medicines Agency, EMA, for conditional marketing authorization of melflufen (melphalan flufenamide) in the EU, based… read more.

European Commission grants conditional approval for Nexpovio to treat multiple myeloma – Karyopharm Therapeutics

Written by | 3 Apr 2021

Karyopharm Therapeutics Inc. announced that the European Commission (EC) has granted conditional marketing authorization for Nexpovio (selinexor), the Company’s first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) medicine,… read more.

FDA approves Pepaxto for patients with relapsed or refractory multiple myeloma – Oncopeptides AB

Written by | 6 Mar 2021

Oncopeptides AB (publ) – announced that the FDA, has approved Pepaxto (melphalan flufenamide, also known as melflufen), in combination with dexamethasone, for the treatment of adult patients with… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.